Dapagliflozin in pediatric heart failure with reduced ejection fraction – A randomized pilot study.

Background: Dapagliflozin (DAPA), a sodium-glucose cotransporter-2 inhibitor, has shown promise in adult patients with heart failure (HF), but its safety and efficacy in children remain underexplored. Methods: In this randomized controlled pilot study, 20 children (aged 1–12 years, median 2.2 years,...

Descripción completa

Detalles Bibliográficos

Publicado en:	Annals of Pediatric Cardiology Vol. 18; no. 4; pp. 323 - 331
Autores principales:	Faisal, Nabeel Valappil, Arumugam, Praveen, Mohankumar, Shivaprasad Pannasamudra, Kadiyani, Lamk, Handa, Ankur, Ramakrishnan, Lakshmy, Datta, Sudip Kumar, Seth, Sandeep, Narang, Rajiv, Gupta, Saurabh Kumar, Ramakrishnan, Sivasubramanian
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	Wolters Kluwer India Pvt Ltd Jul/Aug2025
Acceso en línea:	Ver este registro en EBSCOhost